# US 2026/0055140 A1 · Insulin like growth factor binding protein bioactive peptide fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0055140 A1
- Document ID: US20260055140A1
- Status: Published application
- Kind: A1
- Application number: 19/311,588
- Filed: 2025-08-27
- Published: 2026-02-26
- Earliest claimed: 2019-07-12
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Joseph R. Moskal; Jeffrey S. Burgdorf
- Web page: https://patentgrep.com/patent/US20260055140A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4743: {Insulin-like growth factor binding protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating an autism spectrum disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated peptide having a length of 7 amino acids to 20 amino acids and comprising an amino acid sequence having at least 65% sequence identity to SEQ ID NO: 2.

### Claim 22 (depends on 21)

The method of claim 21, wherein the amino acid sequence has at least 85% sequence identity to SEQ ID NO: 2.

### Claim 23 (depends on 21)

The method of claim 21, wherein the autism spectrum disorder is classical autism or Autistic Disorder; Asperger Syndrome; Childhood Disintegrative Disorder; Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS); Fragile X Syndrome; Rett Syndrome; Kanner syndrome; or Phelan-McDermid Syndrome.

### Claim 24 (depends on 21)

The method of claim 21, wherein the peptide further comprises N-terminal carboxylation, C-terminal amidation, benzylation, one or more halogens, or a combination thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein the peptide is cyclized.

### Claim 26 (depends on 21)

The method of claim 21, wherein the peptide has a length of 7 amino acids to 20 amino acids and comprises the amino acid sequence of PKKLRP (SEQ ID NO: 2).
